Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)
November 02, 2022 08:10 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting
October 24, 2022 08:56 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference
October 07, 2022 07:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease
October 06, 2022 09:27 ET
|
Ocuphire Pharma
Virtual Webinar to Take Place Friday, October 14th @ 11 AM ET Topline Results from ZETA-1 Phase 2b Trial of APX3330 Expected Later in 4Q 2022 FARMINGTON HILLS, Mich., Oct. 06, 2022 (GLOBE...
Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team
September 29, 2022 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting
September 15, 2022 07:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA
September 12, 2022 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy
September 08, 2022 08:00 ET
|
Ocuphire Pharma
Top-line Results are Expected in 4Q 2022 Interim Masked Safety Results Seen Demonstrate Favorable Safety and Tolerability Profile, Consistent with 11 Prior Trials of APX3330 Oral APX3330 has the...
Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 09:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update
August 12, 2022 07:00 ET
|
Ocuphire Pharma
Completed Final Clinical Trials and Pre-NDA FDA Meeting to Support Registration of Nyxol in Reversal of Mydriasis (RM), On Track for Late 2022 NDA Submission and Potential 2023 Approval Positive...